Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Gross Margin (2020 - 2025)

Biofrontera has reported Gross Margin over the past 6 years, most recently at 82.4% for Q4 2025.

  • For Q4 2025, Gross Margin rose 2437.0% year-over-year to 82.4%; the TTM value through Dec 2025 reached 73.71%, up 2356.0%, while the annual FY2025 figure was 73.71%, 2357.0% up from the prior year.
  • Gross Margin for Q4 2025 was 82.4% at Biofrontera, up from 70.74% in the prior quarter.
  • Over five years, Gross Margin peaked at 112.8% in Q4 2023 and troughed at 72.27% in Q4 2022.
  • A 5-year average of 67.81% and a median of 70.74% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: crashed -17030bps in 2022 and later skyrocketed 18507bps in 2023.
  • Year by year, Gross Margin stood at 98.03% in 2021, then tumbled by -174bps to 72.27% in 2022, then skyrocketed by 256bps to 112.8% in 2023, then crashed by -49bps to 58.03% in 2024, then soared by 42bps to 82.4% in 2025.
  • Business Quant data shows Gross Margin for BFRI at 82.4% in Q4 2025, 70.74% in Q3 2025, and 70.74% in Q2 2025.